The results from the present study show that patients with MIBC had significantly higher serum sPD-L1 levels compared to patients with NMIBC, and that patients with metastatic disease had higher serum sPD-L1 levels compared to patients with non-metastatic disease. This evidence concerns the gene SPDL1 and metastatic neoplasm.